Clinical Trial Update: A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial of aflibercept with pemetrexed and cisplatin in advanced carcinoma and non-small cell lung cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Aflibercept (Aflibercept)
• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Advanced Carcinoma, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-12-10